Salehi 2017.

Methods	Randomised, double‐blind, placebo‐controlled trial
Participants	Report states: "Children aged 6 to 10 years old were enrolled in a study in which Duchenne muscular dystrophy (DMD) was diagnosed and approved in them by DNA analysis and muscle biopsy (quadriceps or biceps)" Mean age (SD) in years: coenzyme Q10 8.9 (1.7); placebo 8.6 (1.4) Exclusion criteria: Confirmed or suspected heart disease Other concomitant illness Taking herbal medicine, vitamins or enzymes Arrhythmia on ECG 'Inappropriate view' in echocardiography
Interventions	Coenzyme Q10 (N = 12) Placebo (N = 13) Treatment duration: 6 months
Outcomes	Myocardial performance index
Notes	Location: Tehran, Iran Dates: February 2013 to 2015 Iranian Clinical Trials Registry number: IRCT2015070223018N1 The report suggests that the trial included both male and female participants and describes participants as "suspected of DMD".

ACE inhibitor: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; BMD: Becker muscular dystrophy; DMD: Duchenne muscular dystrophy; ECG: electrocardiograph; MRI: magnetic resonance imaging